Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.
…
continue reading
Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
EP 86: The Year 2022 in Review with Dr Sukh Nijjer
MP3•Episode home
Manage episode 355299137 series 2657277
Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this week’s Parallax Dr Kalra welcomes back Dr Nijjer for their annual review of the most impactful and controversial cardiovascular trials of 2022. Dr Sukh Nijjer is a Consultant Cardiologist in the UK, he is President of the Royal Society of Medicine and Honorary Senior Clinical Lecturer at Imperial College of London. The coronary physiology trial FLAVOUR was presented at ACC.22 by Dr Bon Kwon Koo. This South-Korean study compared the safety and efficacy of FFR and IVUS-guided stenting. Dr Nijjer interprets the findings and outlines the take-home messages by describing his practice. Following this, Dr Kalra and Dr Nijjer look at REVIVED-BCIS2 presented at ESC 2022 by Dr Divaka Perera. Dr Nijjer talks about the complexity of running this study that evaluated whether revascularization by PCI can improve outcomes in patients with ischemic left ventricular systolic dysfunction compared with optimal medical therapy. They distill some of the nuances for practice. Dr Nijjer summarises the all-comers PROTECTED TAVR trial that assessed the use of Sentinel® Cerebral Protection System in patients undergoing TAVR. We learn more about the secondary outcomes and the reception of the results. Dr Kalra shares how the new data impacted his approach. Last, they discuss the implications of Chinese CTS-AMI trial presented at AHA 22 by Dr Yuejin Yang. The trial showed that a traditional remedy, Tongxinluo improved the clinical outcomes of patients with STEMI. Dr Nijjer and Dr Kalra consider the meaning and impact of these trials such as CTS-AMI on Western medicine. How can we interpret some of the controversies from REVIVED? What can we learn from traditional medicinal remedies? What are the key takeaways for clinical practice from the reviewed trials? Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest: @SukhNijjer, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
…
continue reading
118 episodes
MP3•Episode home
Manage episode 355299137 series 2657277
Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this week’s Parallax Dr Kalra welcomes back Dr Nijjer for their annual review of the most impactful and controversial cardiovascular trials of 2022. Dr Sukh Nijjer is a Consultant Cardiologist in the UK, he is President of the Royal Society of Medicine and Honorary Senior Clinical Lecturer at Imperial College of London. The coronary physiology trial FLAVOUR was presented at ACC.22 by Dr Bon Kwon Koo. This South-Korean study compared the safety and efficacy of FFR and IVUS-guided stenting. Dr Nijjer interprets the findings and outlines the take-home messages by describing his practice. Following this, Dr Kalra and Dr Nijjer look at REVIVED-BCIS2 presented at ESC 2022 by Dr Divaka Perera. Dr Nijjer talks about the complexity of running this study that evaluated whether revascularization by PCI can improve outcomes in patients with ischemic left ventricular systolic dysfunction compared with optimal medical therapy. They distill some of the nuances for practice. Dr Nijjer summarises the all-comers PROTECTED TAVR trial that assessed the use of Sentinel® Cerebral Protection System in patients undergoing TAVR. We learn more about the secondary outcomes and the reception of the results. Dr Kalra shares how the new data impacted his approach. Last, they discuss the implications of Chinese CTS-AMI trial presented at AHA 22 by Dr Yuejin Yang. The trial showed that a traditional remedy, Tongxinluo improved the clinical outcomes of patients with STEMI. Dr Nijjer and Dr Kalra consider the meaning and impact of these trials such as CTS-AMI on Western medicine. How can we interpret some of the controversies from REVIVED? What can we learn from traditional medicinal remedies? What are the key takeaways for clinical practice from the reviewed trials? Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest: @SukhNijjer, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
…
continue reading
118 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.